A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
Authors:
- de ManDMde Man
- Robert A.RARobert A.
- Patrick MarcellinPMPatrick Marcellin
- Flavio HabalFHFlavio Habal
- Paul DesmondPDPaul Desmond
- Teresa WrightTWTeresa Wright
- Toby RoseTRToby Rose
- Regina JurewiczRJRegina Jurewicz
- Clarence YoungCYClarence Young
- 1 August 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 32 (2) , 413-417
Abstract
We conducted a randomized, placebo-controlled clinical study evaluating famciclovir (500 mg 3 times daily and 1.5 g once daily) for 1 year (6 months post-treatment follow-up) in patients with chronic hepatitis B e antigen (HBeAg)-positive hepatitis B virus (HBV) infection. The study was conducted in 80 centers in North America, Europe, and Australia/New Zealand. A total of 417 patients with histologically documented chronic hepatitis B (histologic activity index [HAI] 9.5-11.0) received famciclovir (500 mg 3 times daily or 1.5 g once daily) or placebo. Famciclovir 500 mg 3 times daily significantly reduced HBV DNA and median HAI scores versus placebo. By week 8, median HBV DNA decreased from 1,645 to 283 MEq/mL (famciclovir 500 mg 3 times daily) and from 1,147 to 304 MEq/mL (famciclovir 1.5 g once daily), while increasing for placebo (1,617 to 1,685 MEq/mL). Median change in HBV DNA at the end of therapy was −76% (famciclovir 500 mg 3 times daily;P< .01) and −60% (famciclovir 1.5 g once daily;P= .25) versus −37% for placebo. Median change in HAI was −1.5 points (famciclovir 500 mg 3 times daily;P= .02) and −1.0 point (famciclovir 1.5 g once daily;P= .35) and zero for placebo. Fifty percent of patients receiving famciclovir 500 mg 3 times daily (P= .07) and 43% receiving 1.5 g once daily (P= .41) experienced ≥2 points improvement in HAI versus 37% for placebo. Nine percent of patients treated with famciclovir 500 mg 3 times daily underwent anti-HBeAg seroconversion with undetectable HBV DNA at end of follow-up versus 3% in the placebo group (P= .05). Famciclovir was well tolerated; the incidence of post-treatment alanine transaminase (ALT) elevations was comparable with placebo. In conclusion, famciclovir 500 mg 3 times daily gave modest suppression of viral replication, but translated into significant histologic improvement in median HAI score at 1 year.Keywords
This publication has 12 references indexed in Scilit:
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis be-antigen (HBeAg) seroconversionGastroenterology, 1998
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- Hepatitis B: Treatment for the 21st CenturyAntiviral Chemistry and Chemotherapy, 1997
- In vitro evaluation of combination therapies against hepatitis B virus replicationAntiviral Research, 1996
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis BAnnals of Internal Medicine, 1993
- Hepatitis B virusDigestive Diseases and Sciences, 1992
- A cell culture assay for compounds which inhibit hepatitis B virus replicationAntiviral Research, 1991
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981